We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed the most recent trading day at $55.55, moving +1.29% from the previous trading session. The stock lagged the S&P 500's daily gain of 2.59%. Elsewhere, the Dow gained 2.66%, while the tech-heavy Nasdaq added 0.12%.
Heading into today, shares of the pharmaceutical had lost 9.64% over the past month, lagging the Medical sector's loss of 3.87% and the S&P 500's loss of 9.22% in that time.
Astrazeneca will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.78, up 44.44% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $10.73 billion, up 8.73% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.31 per share and revenue of $44.04 billion. These totals would mark changes of +24.91% and +17.7%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Astrazeneca is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Astrazeneca is currently trading at a Forward P/E ratio of 16.58. This represents a premium compared to its industry's average Forward P/E of 12.13.
It is also worth noting that AZN currently has a PEG ratio of 1.06. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.78 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 86, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow AZN in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
Astrazeneca (AZN - Free Report) closed the most recent trading day at $55.55, moving +1.29% from the previous trading session. The stock lagged the S&P 500's daily gain of 2.59%. Elsewhere, the Dow gained 2.66%, while the tech-heavy Nasdaq added 0.12%.
Heading into today, shares of the pharmaceutical had lost 9.64% over the past month, lagging the Medical sector's loss of 3.87% and the S&P 500's loss of 9.22% in that time.
Astrazeneca will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.78, up 44.44% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $10.73 billion, up 8.73% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.31 per share and revenue of $44.04 billion. These totals would mark changes of +24.91% and +17.7%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Astrazeneca is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Astrazeneca is currently trading at a Forward P/E ratio of 16.58. This represents a premium compared to its industry's average Forward P/E of 12.13.
It is also worth noting that AZN currently has a PEG ratio of 1.06. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.78 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 86, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow AZN in the coming trading sessions, be sure to utilize Zacks.com.